I did Mate, I agree it's next generation for sure.Jen was...

I did Mate, I agree it's next generation for sure.

Jen was clearly excited and explained the licensing as transformative covering 10 difference disease areas, blood and solid. Good to see CHM again delivering on commitments by securing another asset(s) before the end of the year. NK cells are an exciting place to be growing the pipeline especially from a safety perspective (not that CHM-1101 had to much trouble with that). They also have a unique ability to recruit the immune system to mount an additional response to kill tumour cells. Allogeneic therapies save up to 4 weeks in the process of getting the therapy into the arm. For those new, This time is saved because manufacturing autologous cells from patients takes more time. I managed to fit the webinar into my day yesterday but haven’t had time to explore too much further into the asset. Looks to be novel, very strategic and builds 4 new NK assets including arming the NK-Car with CLTX and CDH17 in two of the indications.

Will be very interesting to see how the natural killer cells counteract the TME (tumor micro environment) coupled with CLTX’s ability to bind to certain cancers. The key here again is CHM’s ability to source well-developed opportunities. Phase I is complete for the CORE-NK platform. This maybe explains why PH put the pre-clinical staged INK-NK cell program into another company and not CHM earlier this year. Jen was asked “do any of CHM’s portfolio need to use a modular car program in their development” She stated that all assets have a very good safety profile so modular will not be needed.

Reading between the lines it’s clear CHM and their experienced team are privy to the phase I trial results already (due early next year). Good time to be topping up and making an entry as CHM is shaping up to be an emerging global cell therapy player and a clear ASX cell therapy leader. There will be plenty of news flow into next year. I’d like to see how the coverage valuations firms like Edison look at the investment proposition now with these additional assets especially as CORE-NK is already phased I complete.

Good luck all!